

Index

A

Acute lymphoblastic leukemia (ALL), 64
Acute myeloid leukemia (AML), 63, 212
 CLL, 64
 CML, 64
 temozolomide, 235
 veliparib, 235
Adenomatous polyposis coli (APC), 126
Alternative lengthening of telomeres (ALT), 211
Amphiregulin (AREG), 5
Anaplastic lymphoma kinase (ALK), 41, 72
Antibody-dependent cell-mediated cytotoxicity (ADCC), 6
Anticancer drug, 280
Antitumor immunity, 281
Aspirin, 136, 137
Ataxia telangiectasia and Rad3 (ATR), 204
 ATM pathway, 219
 ATRIP, 205
 BLM, 205
 cell-cycle regulation, 206
 chemotherapeutic combinations, 215
 Chk1 inhibitors, 218
 vs Chk1 targeting, 223
 clinical studies, 219, 220
 complete abolition, 207
 development of, 211
 evaluation of, 211
 FANCM, 205
 potential mechanisms, 223
 precision medicine, 224
 preclinical studies, 212, 213
 proteins downstream, 205
 replication stress, 206
 role of, 204
 Seckel syndrome, 207
 single-agent Chk1 inhibition, 212
 single-agent efficacy, 212
 synthetic lethality
 double-stranded DNA repair defects, 209
 G1/S cell-cycle checkpoint defects, 208
 markers sensitivity, 209
 TOPBP1, 205
 uses of, 224
Ataxia telangiectasia mutated (ATM), 209
AT-rich interaction domain 1A (ARID1A), 209

ATR-interacting protein (ATRIP), 205
Autophagic vacuole (AV), 265
Autophagy
 chloroquine, 264
 drug targets, 267
 functions of, 262
 hydroxychloroquine, 264
 implications, 267
 machinery, 260
 novel therapies, 267
 roles of, 269
 STAT3, 266
 transformation, 263
 tumor suppression, 263

B

B-cell lymphoma 2 (BCL-2), 64
B-cell lymphoma 2 (Bcl-2), 137
B-cell lymphoma-extra large (BCL-XL), 64
Betacellulin (BTC), 5
Biomarkers, 46, 76
Bloom syndrome protein (BLM), 205
Bone marrow plasma cells (BMPCs), 265
Breast cancer, 130, 191
 aspirin, 137
 COX-2, 134
 pro-apoptotic genes, 197
 PTEN, 133
 TCGA, 130

C

Cancer
 autophagy
 chloroquine, 264
 drug targets, 267
 functions of, 262
 hydroxychloroquine, 264
 implications, 267
 machinery, 260
 novel therapies, 267
 roles of, 269
 STAT3, 266
 transformation, 263
 tumor suppression, 263
 role of, 260
Cancer cells, 191, 279

- Cancer stem cells (CSCs), 172
 Chaperone-mediated autophagy (CMA), 260
 Chemoresistance, 197, 219
 epigenetics of, 197
 Chemosensitization
 DNA trapping, 236
 SSBs, 234
 Chemotherapy, 194
 Chloroquine (CQ), 264
 Chronic lymphocytic leukemia (CLL), 64, 209
 Chronic myeloid leukemia (CML), 64
 Circulating tumor cells (CTCs), 265
 Colorectal cancer (CRC), 45
 Colorectal cancer (CRCs)
 chemopreventive strategy, 125
 FAP, 124
 key drivers, 129
 oncogenic signaling, 126
 PI3K signaling pathway, 127
 PIK3CA
 APC, 130, 131
 aspirin, 136
 breast cancer, 130, 132
 COX-2, 134
 DNAH5, 130, 131
 FAT4, 130, 131
 FBXW7, 130, 131
 K-Ras, 130, 131
 LRP1B, 130, 131
 LRP2, 130, 131
 PIK3CA, 130, 131
 SYNE1, 130, 131
 TP53, 130, 131
 COX
 COX-1, 134
 COX-2, 134
 Cyclin B1-cyclin-dependent kinase (Cdk1), 206
 Cyclin-dependent kinase (CDK1), 10
 Cyclooxygenase (COX), 124
 Cyndromatosis (CYLD), 276
 Cytosolic (CYT)
 CYT-1, 14, 15
 CYT-2, 14, 15
- D**
 Damage-associated molecular patterns (DAMPs), 266, 276
 Dendritic cells (DCs), 281
 DNA-binding domain inhibitors (DBDI), 147
 DNA damage response (DDR), 204
 DNA methylation
 BRCA1, 191
 in breast cancer, 191
 cancer cells, 191
- CpG, 189
 epigenetic regulation, 189
 epigenetic therapy
 in breast cancer treatment, 192
 cancer therapy, 199
 chemotherapy, 194
 sensitization, 194
 neoplastic transformation, 191
 Dorsal root ganglion (DRG), 36
 Double-stranded DNA breaks (DSBs), 209, 233, 236
 Drug resistance, JNK pathway
 clinical trials, ATP-competitive inhibitors, 94
 isoforms, 89
 oncogenesis, 93
 peptide inhibitors, 96
 scaffold proteins, 90
 structure, 89
 substrates of, 91
 tumor suppressive role, 93
 upstream activation, 90
 DSBs. *See* Double-stranded DNA breaks (DSBs)
- E**
 Epidermal growth factor receptor (EGFR), 102, 126, 148
 aberrant activation, 5, 6
 amphiregulin, 5
 betacellulin, 5
 EGF, 5
 epigen, 5
 epiregulin, 5
 HNSCC, 5, 8
 importance of, 6
 inhibition, 9
 internalization, 6
 kinase domain, 5
 LUSC, 5, 8
 NSCLC, 7
 N-terminal domain, 5
 osimertinib, 6
 paracrine secretion, 6
 primary classes, 6
 subsequent degradation, 6
 TGF- α , 5
 Epigen (EPGN), 5
 Epigenetic therapy, 192
 in breast cancer treatment, 192
 cancer therapy, 199
 chemotherapy, 194
 sensitization, 194
 Epiregulin (EREG), 5
 Epithelial-to-mesenchymal transition (EMT), 65
 Extracellular signal-related kinase (ERK), 62, 88

F

Familial adenomatous polyposis (FAP), 124
 Fanconi anemia (FA) complementation group D2 (FANCD2), 233
 Fanconi anemia complementation group M protein (FANCM), 205
 FDA. *See* Food and Drug Administration (FDA)
 FGFR substrate 2 (FRS2), 103
 Fibroblast growth factor (FGF), 33
 Fibroblast growth factor receptor (FGFR), 72, 148
 activating invasion and metastasis, 103
 avoiding immune destruction, 109
 clinical implications, 104
 enabling replicative immortality, 103
 evading growth suppressors, 109
 HPSGs, 103
 human cancers, 104
 intracellular signaling pathway, 103
 solid tumors, 103
 sustaining proliferative signaling, 109
 tumor-promoting inflammation, 103
 Food and Drug Administration (FDA), 6, 158

G

Gastrointestinal stromal tumor (GIST), 68
 Glioblastoma multiforme (GBM), 63, 250
 G protein-coupled receptors (GPCR), 90, 127, 172
 Growth arrest-specific protein 6 (GAS6), 62
 Growth factor receptor-bound protein 2 (GRB2), 103

H

H2A family member X (H2AX), 233
 Head and neck squamous cell carcinoma (HNSCC), 5, 91, 155
 cetuximab-resistant, 158
 cetuximab-sensitive, 158
 clinical trials, 12
 preclinical models, 8
 treatment of, 8, 157
 xenograft model, 159
 Heparin-binding EGF-like growth factor (HB-EGF), 5
 Heparin sulfate proteoglycans (HPSGs), 103
 Hepatocellular carcinoma (HCC), 172
 Hepatocyte growth factor (HGF)
 β -chain, 27
 biomarkers, 46
 cancer therapy
 activation inhibitors, 39
 inhibitors, 39
 MET antagonists, 40
 MET kinase inhibitors, 40
 chromosome 7, 27
 cMET

 activation loop, 37
 amplification, 38
 fusion protein, 38
 germline mutations, 37
 Grb2 docking site, 36
 internalization, 28–30
 juxtamembrane domain, 31
 overexpression, 38
 recycling of, 31
 Gln-Asp-Tyr, 27
 HGF-CMET pathway
 colorectal cancer, 45
 lung cancer, 42
 PDAC, 44
 renal cancer, 43
 kidney, 34
 liver, 34
 MAPK, 30
 muscle, 33
 nervous tissue, 36
 NK1, 27
 N-terminal domain of, 27
 overexpression, 39
 PI3K-Akt, 30
 placenta, 32
 receptor shedding, 31
 single-chain 83 kDa protein, 27
 splice variants, 28
 STAT3, 30
 testis, 36
 Hereditary nonpolyposis colorectal cancer (HNPCC), 130
 High-grade serous ovarian cancer (HGSOC), 232
 High-mobility group box 1 (HMGB1), 266
 Hippo signaling pathway
 cancer chemotherapy
 LATS activation, 174
 MST activation, 174
 proteins regulating, 178
 TAZ-TEAD interaction, 177
 canonical core cascade, 170
 chemotherapeutic drug resistance
 LATS, 173
 MST, 173
 TAZ, 174
 YAP, 174
 chemotherapy, 179
 in human cancer, 172
 upstream regulators, 171
 HNSCC. *See* Head and neck squamous cell carcinoma (HNSCC)
 Homologous recombination (HR), 233
 Homologous recombination deficiency (HRD), 232
 Homologous recombination repair (HRR), 209

Human epidermal growth factor receptor (HER)

ability of, 4

EGFR

aberrant activation, 5, 6

amphiregulin, 5

betacellulin, 5

EGF, 5

epigen, 5

epiregulin, 5

HNSCC, 5, 8

importance of, 6

inhibition, 9

internalization, 6

kinase domain, 5

LUSC, 5, 8

NSCLC, 7

N-terminal domain, 5

osimertinib, 6

paracrine secretion, 6

primary classes, 6

subsequent degradation, 6

TGF- α , 5

HER2

CDK1, 10

development of, 10

ERBB2 gene, 9

gastric cancer, 10

imerization partner, 12

lapatinib, 10

preclinical research, 10

STAT3, 10

TKIs, 10

treatment of, 10

HER3

CDX-3379, 12

clinical testing, 11

development of, 11

kinase activity, 11

kinase domain, 12

observation of, 13

PI3K, 13

PI3K activity, 12

TKIs, 12

HER4

BTC, 14

CYT-2 isoform, 14

cytosolic region, 15

ERG, 14

HB-EGF, 14

ICD, 14, 15

juxtamembrane, 14

NRG1-4, 14

NRG4, 16

prognostic implications, 13

roles of, 13

subcellular localization, 16

Hydroxychloroquine (HCQ), 264

antitumor effects, 267

PBMCs, 265

steady-state concentrations, 264

toxicity of, 264

Hypoxia-induced factor 1 α (HIF-1 α), 266

I

Immunogenic cell death (ICD), 266

Immunosuppression, 73

Immunotherapy, 281

Inducible NOS (iNOS), 32

Inflammatory bowel disease (IBD), 134

Iniparib, 237

Interleukin-6 receptor (IL-6R), 148

Intracellular domains (ICDs), 3

iPOND method, 205

J

Janus kinases (JAKs), 146

Juxtamembrane (JM)

JM-a, 14

JM-b, 14

JM-c, 14

JM-d, 14

K

Kidney, 34

L

Lapatinib, 10

Large cell carcinoma (LCC), 7

LATS, 173, 174

Linear ubiquitin chain assembly complex (LUBAC), 276

Liver, 34

Liver X receptor (LXR), 64

M

Mammalian target of rapamycin (mTOR), 261

Mast cell tumors (MST), 173, 174

Metastatic colorectal cancer (mCRC), 126

Microphthalmia transcription factor (MITF), 44

Mitochondrial permeability transition (MPT), 276

Mitogen-activated protein kinase (MAPK), 30, 70, 88

Mixed lineage kinase domain-like (MLKL), 277

Multitargeting kinase activity (MTKI), 110

Muscle, 33

N

National Cancer Institute (NCI), 130

National Human Genome Research Institute
(NHGRI), 130

- Necroptosis
 anticancer drug, 280
 antitumor immunity, 281
 cancer cells, 279
 characteristic of, 277
 MLKL, 281
 RIPK3, 276
 tumor-suppressive role, 279
- Nervous tissue, 36
- Neuregulin 1 (NRG1), 12
- Neuregulin 4 (NRG4), 16
- Niraparib, 239
- Nonhomologous end joining (NHEJ), 209, 235
- Non-small cell lung cancer (NSCLC), 5, 31, 63, 148, 171, 235
 clinical trial, 7
 crizotinib trial, 38
 EGFR alterations, 7
 objective response rate, 7
 progression-free survival, 7
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 124
 chemopreventive properties, 125
 role of, 136
- N-terminal and kringle 1 domain (NK1), 27
- N-terminal domain (NTD), 159
 chromatin remodeling, 159
 development of, 160
 therapeutic potential, 160
- N-terminal domain inhibitors (NDIs), 147
- Nuclear factor kappa B (NF- κ B), 134
- Nuclear magnetic resonance (NMR), 151
- O**
- Olaparib, 237
- Oncogenesis, 93
- Osimertinib, 6
- P**
- Pancreatic ductal adenocarcinoma (PDAC), 44
- Pancreatic stellate cells (PSCs), 44
- Patient-derived xenotransplantation (PDX), 209
- Peripheral blood mononuclear cells (PBMCs), 238, 264
- Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 6
- Phosphatidylinositol-3-kinase (PI3K), 28, 30, 127
- Phosphatidylinositol 3-kinase (PtdIns3K), 261
- Phosphatidylserine (PtdSer), 62
- Phosphoinositide 3-kinase-related kinase (PIKK), 204
- Phospholipase C gamma (PLC γ), 103
- Phosphorylated AXL (pAXL), 67
- Placenta, 32
- Pleckstrin homology (PH), 127
- Poly(ADP-ribose) (PAR), 235
- Poly-(ADP-ribose) polymerase (PARP), 215
- Poly(ADP-ribose) glycohydrolase (PARG), 233
- Poly(ADP-ribose) polymerase (PARP), 232
 BER, 235
 chemosensitization
 DNA trapping, 236
 SSBs, 234
 clinical development of, 233
 combination of, 232
 degrees of, 234
 human tumor cell lines, 235
 inhibitors and chemotherapy combinations
 clinical benefits, 247
 iniparib, 237
 niraparib, 239
 olaparib, 237
 rucaparib, 240
 talazoparib, 241
 toxicity, 246
 veliparib, 238
 NHEJ, 235
 nonchemotherapy combinations, 249
 NSCLC, 235
 role of, 233
 synergistic DNA damage, 234
- Precision medicine, 224
- Progression-free survival (PFS), 237
- Prostaglandin-E2 (PGE2), 125, 134
- Prostaglandin-H2 (PGH2), 134
- Protein kinase-1 (PDK1), 127
- Proteins regulating, 178
- R**
- Reactive oxygen species (ROS), 263
- Receptor tyrosine kinases (RTKs), 2, 127
 aberrant activation, 6
 agents, 74
 approaches, 74
 biomarkers, 76
 conventional therapies, 69
 dual targets, 76
 EMT, 65
 HER family, 5
 in immunosuppression, 73
 non-HER family, 5
 role of, 66
 TAM receptors, 63
 targeted therapies, 68, 71
 traditional chemotherapy, 67
 trastuzumab primarily inhibits ligand-independent dimerization, 10
 tumor-suppressive role, 13
- Renal cell carcinoma (RCC), 41, 43
- Replication protein A (RPA), 205
- Replication stress (RS), 206

RIP homotypic interaction motif (RHIM), 277
Rucaparib, 240

S

Scaffold proteins, 90
Scatter factor (SF), 27
Second kringle domain (NK2), 27
Sensitization, 194
SH2 domain inhibitors (SDI), 147
 nonpeptidic small-molecule, 151
 OPB-31121, 155
 OPB-51602, 155
 peptidomimetics, 151
Short hairpin RNA (shRNA), 64, 173
Signal transducer and activator of transcription 3 (STAT3), 10, 266
 antisense, 160
 antisense oligonucleotides, 157
 Bcl-X_L, 157
 clinical utility, 161
 cyclic, 159
 EGFR, 148
 FGFR, 148
 hemical structures, 147, 149
 IL-6R, 148
 NSCLC, 148
 NTD, 159
 pharmacodynamic effects, 159
 pY*705 residues, 154
 SH2 domain, 146, 147
 STAT3, 155
 structure of, 151
 synergistic activity, 158
 systemic administration, 159
 therapeutic inhibition, 161
 toxicology studies, 159
 U87, 148
Signal transducer and activator of transcription 5A (STAT5A), 14
Single-nucleotide polymorphism (SNP), 279
Single-strand breaks (SSBs), 233
 formation of, 236
 topo1-dependent, 234
Single-stranded DNA (ssDNA), 205
Small interfering RNA (siRNA), 67

Small molecular drugs (SMDs), 178
Small-molecule enhancers of rapamycin (SMERs), 262
Soluble cMET (s-cMET), 32
Squamous cell carcinoma of the lung (LUSC), 5
SRC-homology 2 (SH2), 146
STAT3 inhibitory compound (STAT3IC), 155
Stress-activated MAP kinase (SAPK), 88
Suppressor of cytokine signaling (SOCS), 73
Synthetic lethality, 207
 double-stranded DNA repair defects, 209
 G1/S cell-cycle checkpoint defects, 208
 markers sensitivity, 209

T

Talazoparib, 241
TAZ, 174
T-cell acute lymphoblastic leukemia (T-ALL), 94
T-cell receptors (TCRs), 280
Temozolomide, 235
Testis, 36
TKIs. *See* Tyrosine kinase inhibitors (TKIs)
TNF receptor (TNFR), 194
Toll-like receptor 3 (TLR3), 276
Toll-like receptors (TLRs), 276
Topoisomerase 2-binding protein 1 (TOPBP1), 205
Toxicity, 246
Transcriptional enhancer associate domain (TEAD), 170
Transforming growth factor- α (TGF- α), 5
Transforming growth factor- β (TGF- β), 90
Tumor necrosis factor (TNF), 194
Tyrosine kinase inhibitors (TKIs), 6, 7, 67
Tyrosyl-DNA-phosphodiesterase (TDP1), 234

U

UV radiation resistance-associated gene (UVRAG), 261

V

Vascular endothelial growth factor (VEGF), 91
Vascular endothelial growth factor receptor (VEGFR), 66
Veliparib, 235, 238
Verteporfin (VP), 178

Y

Yes-associated protein (YAP), 170, 174, 178